Emoxypine succinate |
| Catalog No.GC67214 |
Emoxypine succinate는 항산화제입니다. 821d96072c2d58d8970e76f526b0f6b8Emoxypine succinate는 외상 후 연구에 사용할 수 있습니다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 127464-43-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Emoxypine succinate is an antioxidant. Emoxypine succinate can be used for the research of post-traumatic[1].
Emoxypine succinate shows reactive oxygen species overproduction and disruption of the mitochondrial inner membrane due to the decreasing of transmembrane potential[1].
Emoxypine succinate (i.p.; 40 mg/kg; 1 time per day, 14 days) decreases the production of reactive oxygen species, mitochondrial transmembrane potential percentage of leukocyte and the percentage of FITC Annexin V- positive cells of leukocyte suspension[1].
| Animal Model: | Rats[1] |
| Dosage: | 40 mg/kg |
| Administration: | Intraperitoneal, 1 time per day, 14 days |
| Result: | Significantly increased the percentage of Annexin V-positive cells, reduced the apoptotic percentage of white blood cells and decreased the production of reactive oxygen species by leukocytes. |
[1]. Krynytska, et al. Features of leukocytes' apoptosis and emoxypine succinate efficacy in case of combined trauma of the chest and both thighs in rats. Bangladesh Journal of Medical Science, (2019). 18(2), 244-251.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *